GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Quick Ratio

Esperion Therapeutics (LTS:0IIM) Quick Ratio : 1.78 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Esperion Therapeutics's quick ratio for the quarter that ended in Mar. 2024 was 1.78.

Esperion Therapeutics has a quick ratio of 1.78. It generally indicates good short-term financial strength.

The historical rank and industry rank for Esperion Therapeutics's Quick Ratio or its related term are showing as below:

LTS:0IIM' s Quick Ratio Range Over the Past 10 Years
Min: 0.87   Med: 4   Max: 40.33
Current: 1.78

During the past 13 years, Esperion Therapeutics's highest Quick Ratio was 40.33. The lowest was 0.87. And the median was 4.00.

LTS:0IIM's Quick Ratio is ranked better than
61.57% of 1072 companies
in the Drug Manufacturers industry
Industry Median: 1.32 vs LTS:0IIM: 1.78

Esperion Therapeutics Quick Ratio Historical Data

The historical data trend for Esperion Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Quick Ratio Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.20 3.51 4.02 2.29 0.87

Esperion Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.21 1.74 1.21 0.87 1.78

Competitive Comparison of Esperion Therapeutics's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Quick Ratio falls into.



Esperion Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Esperion Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(201.065-65.623)/156.224
=0.87

Esperion Therapeutics's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(365.606-73.095)/164.512
=1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics  (LTS:0IIM) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Esperion Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (LTS:0IIM) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics (LTS:0IIM) Headlines

No Headlines